Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mickael Ohanna

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancers|July 27, 2022
Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma PathogenesisMickael Ohanna, Pierric Biber, Marcel Deckert
Pigment Cell & Melanoma Research|November 3, 2010
Fitting MITF regulation of PDE4D3 into the skin pigmentation puzzleMickael Ohanna, Corine Bertolotto, Robert Ballotti
Pigment Cell & Melanoma Research|December 10, 2009
Fifteen-year quest for microphthalmia-associated transcription factor target genesYann Cheli, Mickael Ohanna, Robert Ballotti, et al.
Pigment Cell & Melanoma Research|April 20, 2011
BRCA1 is a new MITF target geneLaurent Beuret, Mickael Ohanna, Thomas Strub, et al.
American Journal of Physiology. Cell Physiology|May 15, 2007
S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnoverVirginie Mieulet, Mila Roceri, Catherine Espeillac, et al.
Molecular Cancer Therapeutics|April 29, 2018
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting TherapiesRobin Didier, Aude Mallavialle, Rania Ben Jouira, et al.
Cell Reports|October 2, 2025
USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilizationPierric Biber, Alexandrine Carminati, Walaa Mohager, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 30, 2024
Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradationJessy Sirera, Saharnaz Sarlak, Manon Teisseire, et al.
EMBO Molecular Medicine|December 27, 2021
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanomaIlona Berestjuk, Margaux Lecacheur, Alexandrine Carminati, et al.
EMBO Molecular Medicine|February 14, 2022
Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanomaSerena Diazzi, Alberto Baeri, Julien Fassy, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancers|July 27, 2022
Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma PathogenesisMickael Ohanna, Pierric Biber, Marcel Deckert
Pigment Cell & Melanoma Research|November 3, 2010
Fitting MITF regulation of PDE4D3 into the skin pigmentation puzzleMickael Ohanna, Corine Bertolotto, Robert Ballotti
Pigment Cell & Melanoma Research|December 10, 2009
Fifteen-year quest for microphthalmia-associated transcription factor target genesYann Cheli, Mickael Ohanna, Robert Ballotti, et al.
Pigment Cell & Melanoma Research|April 20, 2011
BRCA1 is a new MITF target geneLaurent Beuret, Mickael Ohanna, Thomas Strub, et al.
American Journal of Physiology. Cell Physiology|May 15, 2007
S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnoverVirginie Mieulet, Mila Roceri, Catherine Espeillac, et al.
Molecular Cancer Therapeutics|April 29, 2018
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting TherapiesRobin Didier, Aude Mallavialle, Rania Ben Jouira, et al.
Cell Reports|October 2, 2025
USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilizationPierric Biber, Alexandrine Carminati, Walaa Mohager, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 30, 2024
Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradationJessy Sirera, Saharnaz Sarlak, Manon Teisseire, et al.
EMBO Molecular Medicine|December 27, 2021
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanomaIlona Berestjuk, Margaux Lecacheur, Alexandrine Carminati, et al.
EMBO Molecular Medicine|February 14, 2022
Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanomaSerena Diazzi, Alberto Baeri, Julien Fassy, et al.
Pageof 1